Trademark Overview
On Wednesday, August 6, 2025, a trademark application was filed for MYRICX BIO with the United States Patent and Trademark Office. The USPTO has given the MYRICX BIO trademark a serial number of 79442817. The federal status of this trademark filing is NEW APPLICATION - ASSIGNED TO EXAMINER as of Saturday, February 7, 2026. This trademark is owned by Myricx Pharma Limited. The MYRICX BIO trademark is filed in the Pharmaceutical Products, Advertising, Business and Retail Services, and Computer & Software Services & Scientific Services categories with the following description:
Pharmaceutical and biotechnological preparations; pharmaceutical and biotechnological preparations for the diagnosis and treatment of human diseases; pharmaceutical and biotechnological preparations for the diagnosis and treatment of proliferative human diseases; pharmaceutical and biotechnological preparations for the diagnosis and treatment of diseases including cancer, fibrosis, inflammation, senescence and diseases of aging; antibody drug conjugates (ADCs); antibody drug conjugates (ADCs) for the diagnosis and treatment of human diseases; antibody drug conjugates (ADCs) for the diagnosis and treatment of proliferative human diseases; antibody drug conjugates (ADCs) for the diagnosis and treatment of diseases including cancer, fibrosis, inflammation, senescence and diseases of aging; N-myristoyltransferases (NMT) inhibitors; N-myristoyltransferases (NMT) inhibitors for the diagnosis and treatment of human diseases; N-myristoyltransferases (NMT) inhibitors for the diagnosis and treat...
Commercialisation of pharmaceuticals and biotechnological preparations; commercialisation of pharmaceuticals and biotechnological preparations for the diagnosis and treatment of human diseases; commercialisation of pharmaceuticals and biotechnological preparations for the diagnosis and treatment of proliferative human diseases; commercialisation of pharmaceuticals and biotechnological preparations for the diagnosis and treatment of diseases including cancer, fibrosis, inflammation, senescence and diseases of aging; commercialisation of antibody drug conjugates (ADCs) and N-myristoyltransferases (NMT) inhibitors; consultancy, advisory and information services relating to the aforesaid services.
Scientific and biomedical research; scientific and biomedical research in the field of human diseases; scientific and biomedical research in the field of proliferative human diseases; scientific and biomedical research in the field of diseases including cancer, fibrosis, inflammation, senescence and diseases of aging; development and testing of pharmaceuticals and biotechnological preparations; scientific and technological research, development and testing of pharmaceuticals and biotechnological preparations, including scientific and technological research for their commercialisation; development and testing of pharmaceuticals and biotechnological preparations for the diagnosis and treatment of human diseases; development and testing of pharmaceuticals and biotechnological preparations for the diagnosis and treatment of humandiseases, and scientific and technological research supporting their commercialisation; development and testing of pharmaceuticals and biotechnological preparation...
